Literature DB >> 8840349

Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain.

S V Bhagwat1, S Bhamre, M R Boyd, V Ravindranath.   

Abstract

Flavin-containing monooxygenase (FMO), previously reported both from hepatic and extrahepatic tissues, including brain, catalyze the oxidation of certain xenobiotics and drugs that contain a nucleophilic heteroatom. Psychoactive drugs, including the antidepressant imipramine, are substrates for the brain FMO. Since FMO-mediated metabolism of these drugs might contribute to local pharmacodynamic modulation within the human brain, the metabolism of imipramine by human brain FMO was studied in further detail. In the present study, the FMO activity was determined in human brain microsomes by estimating the actual amount of imipramine N-oxide formed. It was then compared with the corresponding activity measured using substrate (imipramine)-stimulated rates of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation, which was significantly higher than the activity estimated as the amount of N-oxide assayed using high-pressure liquid chromatography (HPLC). The brain FMO activity was measurable only in the presence of detergents (sodium cholate or Lubrol PX) or in microsomes that were freeze-thawed several times. The activity was inhibited by an antibody to rabbit pulmonary FMO, but an antiserum to the rat liver NADPH cytochrome P-450 reductase had no effect indicating that cytochrome P-450 was not involved in the above metabolic pathway. The optimum pH for N-oxidation of imipramine was found to be 8.5; thermolability experiments indicated that the FMO activity was completely lost only after the incubation of brain microsomes at 45 degrees C for 20 minutes. An FMO purified to apparent homogeneity from a human brain had a molecular weight of 71,000 Da. The purified enzyme cross-reacted with the antibody to rabbit pulmonary FMO and efficiently catalyzed the metabolism of imipramine to its N-oxide. The human brain clearly contains an active FMO system, and it is conceivable that such enzymes are significantly involved in the local metabolism and modulation of pharmacological and/or toxic effects of certain xenobiotics, including psychoactive drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840349     DOI: 10.1016/0893-133X(95)00175-D

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  7 in total

Review 1.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

2.  Common polymorphisms in FMO1 are associated with nicotine dependence.

Authors:  Anthony L Hinrichs; Sharon E Murphy; Jen C Wang; Scott Saccone; Nancy Saccone; Joe Henry Steinbach; Alison Goate; Victoria L Stevens; Laura J Bierut
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

3.  Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes.

Authors:  Adam Joseph Bloom; Pan-Fen Wang; Evan D Kharasch
Journal:  Pharmacol Res Perspect       Date:  2019-03-11

4.  Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects.

Authors:  Derrek P Hibar; Jason L Stein; April B Ryles; Omid Kohannim; Neda Jahanshad; Sarah E Medland; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Andrew J Saykin; Clifford R Jack; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2013-06       Impact factor: 3.978

5.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

Review 6.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

7.  Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain.

Authors:  A M Teitelbaum; S E Murphy; G Akk; T B Baker; A Germann; L B von Weymarn; L J Bierut; A Goate; E D Kharasch; A J Bloom
Journal:  Pharmacogenomics J       Date:  2017-03-14       Impact factor: 3.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.